[
  {
    "ts": null,
    "headline": "Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength",
    "summary": "HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.",
    "url": "https://finnhub.io/api/news?id=ef2a3aaaf92c4776c845370bb3c4625e6ad444f077a4f88bf8ad2a39d188311b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755087900,
      "headline": "Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength",
      "id": 136328712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.",
      "url": "https://finnhub.io/api/news?id=ef2a3aaaf92c4776c845370bb3c4625e6ad444f077a4f88bf8ad2a39d188311b"
    }
  },
  {
    "ts": null,
    "headline": "Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Hologic delivered a solid second quarter, surpassing Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this outperformance to improved commercial execution in the Breast Health segment, particularly in imaging and interventional sales, as well as ongoing progress in diagnostics and surgical divisions. CEO Stephen MacMillan emphasized that “the operative word for Hologic in the third quarter was progress,” pointing to a rebound in previously challenged busin",
    "url": "https://finnhub.io/api/news?id=9337e24c655d23d05447e76553c0d22788d0974ea2be1d842b7bfd7e29d6d8bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057326,
      "headline": "Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions",
      "id": 136328859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "Hologic delivered a solid second quarter, surpassing Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this outperformance to improved commercial execution in the Breast Health segment, particularly in imaging and interventional sales, as well as ongoing progress in diagnostics and surgical divisions. CEO Stephen MacMillan emphasized that “the operative word for Hologic in the third quarter was progress,” pointing to a rebound in previously challenged busin",
      "url": "https://finnhub.io/api/news?id=9337e24c655d23d05447e76553c0d22788d0974ea2be1d842b7bfd7e29d6d8bf"
    }
  },
  {
    "ts": null,
    "headline": "HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum",
    "summary": "Medical technology company Hologic (NASDAQ:HOLX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 1.2% year on year to $1.02 billion. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=21b0ee3cd1ce20b82f58a89c88f099dcb4c1c0e2ba226c5864794569ca9a6a1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057223,
      "headline": "HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum",
      "id": 136328860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "Medical technology company Hologic (NASDAQ:HOLX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 1.2% year on year to $1.02 billion. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=21b0ee3cd1ce20b82f58a89c88f099dcb4c1c0e2ba226c5864794569ca9a6a1e"
    }
  }
]